Here’s how analysts see Arbutus Biopharma Corporation (NASDAQ:ABUS) after this past week.

March 14, 2018 - By Linda Rogers

 Here's how analysts see Arbutus Biopharma Corporation (NASDAQ:ABUS) after this past week.

Arbutus Biopharma Corporation (NASDAQ:ABUS) Ratings Coverage

Among 5 analysts covering Arbutus Biopharma (NASDAQ:ABUS), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Arbutus Biopharma had 16 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Market Perform” rating by Leerink Swann given on Friday, August 5. The stock of Arbutus Biopharma Corporation (NASDAQ:ABUS) earned “Neutral” rating by Chardan Capital Markets on Thursday, June 16. The rating was downgraded by Chardan Capital Markets to “Sell” on Friday, July 8. The firm has “Buy” rating by Chardan Capital Markets given on Wednesday, November 30. The rating was maintained by Chardan Capital Markets on Friday, August 4 with “Buy”. The rating was initiated by JMP Securities with “Mkt Outperform” on Wednesday, September 2. The stock has “Sell” rating by Chardan Capital Markets on Monday, May 16. Chardan Capital Markets downgraded the stock to “Neutral” rating in Tuesday, December 13 report. The firm earned “Neutral” rating on Friday, October 14 by Chardan Capital Markets. Wedbush initiated Arbutus Biopharma Corporation (NASDAQ:ABUS) on Friday, August 7 with “Outperform” rating. Below is a list of Arbutus Biopharma Corporation (NASDAQ:ABUS) latest ratings and price target changes.

07/11/2017 Broker: Leerink Swann Rating: Market Perform Old Target: $4 New Target: $5.5 Maintain

The stock decreased 5.83% or $0.35 during the last trading session, reaching $5.65. About 187,524 shares traded. Arbutus Biopharma Corporation (NASDAQ:ABUS) has declined 2.31% since March 14, 2017 and is downtrending. It has underperformed by 19.01% the S&P500.

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus infection in Canada and the United States. The company has market cap of $311.04 million. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). It currently has negative earnings. The companyÂ’s lead candidate is ARB-1467, which is in a Phase II trial to eliminate HBV surface antigen expression in patients chronically infected with HBV.

More notable recent Arbutus Biopharma Corporation (NASDAQ:ABUS) news were published by: which released: “Arbutus Announces Corporate Update and Year-End 2017 Financial Results” on March 14, 2018, also with their article: “Arbutus Announces Departure of Chief Financial Officer; Appoints Interim CFO” published on February 14, 2018, published: “Arbutus Biopharma (ABUS) Settles Litigation with Acuitas Therapeutics” on February 22, 2018. More interesting news about Arbutus Biopharma Corporation (NASDAQ:ABUS) were released by: and their article: “Form 4 Arbutus Biopharma Corp For: Feb 16 Filed by: Cousins Bruce” published on February 21, 2018 as well as‘s news article titled: “Arbutus Announces Conference Call to Provide a Corporate Update and Fourth …” with publication date: March 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: